Imipramine Treatment for Patients With Multi-organ Bodily Distress Syndrome
Status:
Completed
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
The aim of this study is to test the effect of the tricyclic antidepressant Imipramine in
patients with longlasting health problems with no known medical explanation, defined as
multi-organ Bodily distress syndrome (BDS). Pharmacological treatment of patients with BDS
have never been tested, and Imipramine i low dosage (10-75 mg) has the potential of reducing
both pain and other symptoms of bodily distress for patients with BDS. Control conditions are
pill placebo. Study duration is 19 weeks for each of the 140 patients. End point is 13 weeks,
i.e. after 10 weeks of 25-75 mg study drug.